Dr. William Ricke’s laboratory has discovered a potential method to treat castration resistant prostate cancer (CRPC), by targeting a novel molecular mechanism involving RNA-binding protein. Drs. Ricke, Vellky, and colleagues have described DDX3 (DEAD-box helicase 3 X-linked) as a key repressor of AR protein translation that may be targetable for sensitizing AR low/negative CRPC subtypes to AR-directed therapies.
“The emergence of AR low/negative castration-resistant prostate cancer has led to grim prognoses for men around the world,” said Ricke. “We hope this discovery is a significant step to providing effective therapeutics for those facing castration resistant diseases including prostate cancer and Benign Prostatic Hyperplasia.”
See full publication here: https://www.pnas.org/content/117/45/28092